About CytoDyn
CytoDyn is a company based in Vancouver (United States) founded in 2002.. The company has 13 employees as of May 31, 2024. CytoDyn has completed 1 acquisition, including ProstaGene. CytoDyn offers products and services including Leronlimab. CytoDyn operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, Adaptive Biotechnologies, C4 Therapeutics and CareDx, among others.
- Headquarter Vancouver, United States
- Employees 13 as on 31 May, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cytodyn Inc.
-
Annual Revenue
$00as on May 31, 2024
-
Net Profit
$3.75 M107.52as on May 31, 2024
-
EBITDA
$11.34 M162.9as on May 31, 2024
-
Latest Funding Round
$17.5 M (USD), Post-IPO
Mar 05, 2026
-
Investors
-
Employee Count
13
as on May 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CytoDyn
CytoDyn is a publicly listed company on the OTC with ticker symbol CYDY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CytoDyn
CytoDyn offers a comprehensive portfolio of products and services, including Leronlimab. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets CCR5 receptor for cancer and inflammation treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of CytoDyn
- Total Funding Total Funding
- Total Rounds 22
- Last Round Post-IPO — $17.5M
-
First Round
First Round
(20 Oct 2009)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2026 | Amount | Post-IPO - CytoDyn | Valuation |
investors |
|
| Apr, 2022 | Amount | Post-IPO - CytoDyn | Valuation |
investors |
|
| Dec, 2021 | Amount | Post-IPO - CytoDyn | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by CytoDyn
CytoDyn has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ProstaGene. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene-based prostate cancer testing and metastasis prevention technologies are developed.
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - CytoDyn
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cytodyn Comparisons
Competitors of CytoDyn
CytoDyn operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, Adaptive Biotechnologies, C4 Therapeutics and CareDx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Medical solutions for transplant patients are developed and provided.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cytodyn
Frequently Asked Questions about CytoDyn
When was CytoDyn founded?
CytoDyn was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Where is CytoDyn located?
CytoDyn is headquartered in Vancouver, United States. It is registered at Vancouver, Washington, United States.
How many employees does CytoDyn have?
As of May 31, 2024, the latest employee count at CytoDyn is 13.
What does CytoDyn do?
CytoDyn was established in 2002 and is based in Vancouver, United States. Operations focus on biotechnology within the pharmaceutical sector, where humanized monoclonal antibodies are developed to address HIV infection. The lead product, PRO 140, is advanced as a treatment option, with antiviral effects observed in clinical settings for men. Entry of the virus into T-cells is inhibited by PRO 140 through blockade of the CCR5 co-receptor.
Who are the top competitors of CytoDyn?
CytoDyn's top competitors include Moderna, Jazz Pharmaceuticals and C4 Therapeutics.
What products or services does CytoDyn offer?
CytoDyn offers Leronlimab.
Is CytoDyn publicly traded?
Yes, CytoDyn is publicly traded on OTC under the ticker symbol CYDY.
How many acquisitions has CytoDyn made?
CytoDyn has made 1 acquisition, including ProstaGene.
What is CytoDyn's ticker symbol?
The ticker symbol of CytoDyn is CYDY on OTC.